Keresty Georgia 4

What Happened Georgia Keresty, a director of Solid Biosciences (SLDB), was granted a derivative award of 77,500 shares on June 10, 2026. The filing reports an acquisition price of $0.00 and lists the transaction as a derivative grant (award), so no cash changed hands at grant reporting.

Key Details

• Transaction date and price: June 10, 2026; 77,500 shares; $0.00 per share (derivative award).
• Filing date: June 11, 2026 (appears timely; Form 4s are due within two business days).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the issuer’s next annual meeting after the grant date, and will vest fully upon specified change-in-control events.
• No 10b5-1 plan, tax withholding, or immediate sale reported in the provided data.

Context This was a grant/award of a derivative (option-like) instrument, not a purchase or sale of already issued common stock. Such awards are commonly used for director compensation and typically vest over time or on specific events; they do not necessarily indicate immediate insider buying or selling.